Published in
American Society of Hematology, Blood, 5(131), p. 525-532
DOI: 10.1182/blood-2017-04-780544
Links
Tools
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies
Journal article published in 2017 by
Giovanni Palladini 
,
Paolo Milani ,
Andrea Foli,
Marco Basset ,
Francesca Russo,
Stefano Perlini,
Giampaolo Merlini
,
Paolo Milani ,
Andrea Foli,
Marco Basset ,
Francesca Russo,
Stefano Perlini,
Giampaolo Merlini
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Exposure to melphalan and bortezomib and quality of response to up-front treatment prolong time to second-line therapy in AL amyloidosis. Patients who need second-line therapy after initial response have a good outcome if they are rescued before cardiac progression.